Regenxbio price target lowered to $17 from $21 at RBC Capital

RBC Capital lowered the firm’s price target on Regenxbio (RGNX) to $17 from $21 and keeps an Outperform rating on the shares after its Q2 results. In DMD, the company’s pivotal trial that may lead to accelerated approval is ongoing, the analyst tells investors in a research note. RBC adds that it continues to like the setup given an undemanding valuation.